The present invention relates to methods for the evaluation of HIV-I Subtype C (HIV- 1-C) treatment. The methods are based on evaluating molecular events at the HIV-I-C gag-protease-reverse transcriptase (GPRT) resulting in altered therapeutic efficacy of investigated anti-retro viral compounds. The methods rely on providing HIV-I-C GPRT RNA and evaluating a treatment either through genotyping or phenotyping methods. Said methods may find a use in the field of diagnostics, drug screening, pharmacogenetics and drug development.
展开▼